Answer FAQs About Insulin for Type 2 Diabetes

April 2023

Insulin is in the spotlight...and you can help answer questions.

Medicare Part D now caps insulin co-pays at $35/month. And manufacturers are rolling out their own co-pay caps...and lower prices.

Plus Rezvoglar (insulin glargine-aglr) will soon join Semglee as a lower-cost interchangeable biosimilar for Lantus.

 

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote